Patil, Nirav
Somasundaram, Eashwar
Waite, Kristin A.
Lathia, Justin D.
Machtay, Mitchell
Gilbert, Mark R.
Connor, James R.
Rubin, Joshua B.
Berens, Michael E.
Buerki, Robin A.
Choi, Serah
Sloan, Andrew E.
Penas-Prado, Marta
Ashby, Lynn S.
Blumenthal, Deborah T.
Werner-Wasik, Maria
Hunter, Grant K.
Flickinger, John C.
Wendland, Merideth M.
Panet-Raymond, Valerie
Robins, H. Ian
Pugh, Stephanie L.
Mehta, Minesh P.
Barnholtz-Sloan, Jill S. http://orcid.org/0000-0001-6190-9304
Funding for this research was provided by:
National Cancer Institute (5P30CA043703-30S1)
NRG Oncology (U10CA180868, U10CA180822, UG1CA189867)
Article History
Received: 15 September 2021
Accepted: 25 October 2021
First Online: 10 November 2021
Declarations
:
: Drs. Ashby, Barnholtz-Sloan, Berens, Blumenthal, Buerki, Choi, Connor, Flickinger, Gilbert, Hunter, Lathia, Machtay, Panet-Raymond, Patil, Penas-Prado, Robins, Rubin, Sloan, Somasundaram, Waite, Wendland and Werner-Wasik have nothing to disclose. Dr. Mehta reports personal (consultant) fees from Mevion, Karyopharm, Tocagen, Astra Zeneca, Blue Earth Diagnostics, Board of Directors from Oncoceutics (with options) outside the submitted work. Dr. Pugh reports Salary support paid to my institution from Millennium, and Pfizer, outside the submitted work.
: Exempt approval was obtained from the University Hospitals Institutional Review Board (IRB) for all analyses presented.
: NRG/RTOG 0525 and NRG/RTOG 0825 for which a written informed consent was obtained for each study subject under IRB approved protocols for each participating NRG study site.